| Saturday, April 29, 2006 |
| Lyrica Approved For The Treatment Of Generalized Anxiety Disorder (GAD) In Europe |
Pfizer Inc said today that the European Commission has approved Lyrica(R) (pregabalin) for the treatment of generalized anxiety disorder (GAD) in adults. In the European Union, it is estimated that nearly 12 million patients suffer from GAD on a yearly basis yet only one-third of these patients are properly diagnosed and even fewer received effective treatment.
Lyrica's approval was based on five randomized double-blind clinical trials involving over 2,000 patients. Data from a combination of five placebo-controlled studies demonstrate that Lyrica provides rapid and sustained efficacy for the treatment of GAD. As early as the first week of treatment, Lyrica was shown to be significantly effective in providing relief of both emotional symptoms, such as depressive symptoms and panic, as well as physical symptoms, including headaches and muscle aches.
"GAD is much more than the normal anxiety people experience under times of stress. It is a chronic, debilitating illness that can greatly disrupt an individual's daily life, yet the disorder is under-treated," said Dr. Stuart Montgomery, Professor of Psychiatry, Imperial College School of Medicine, University of London. "Now that Lyrica is available, we have a new treatment option to help alleviate a broad range of emotional and physical symptoms of this prevalent condition."
Generalized anxiety disorder, which affects an estimated five percent of people at some point in their lives, is a common and chronic psychiatric disorder characterized by excessive worry and tension about everyday routine life events and activities. Physical symptoms include poor sleep and fatigue, while the emotional symptoms include difficulty concentrating, irritability and restlessness. Generalized anxiety disorder occurs more frequently in patients with other chronic medical illnesses, especially those associated with pain conditions. The direct annual healthcare costs associated with GAD in Europe are approximately $1.5 billion.
"Lyrica represents an innovative treatment advance for patients suffering from generalized anxiety disorder," said Dr. Joseph Feczko, president of Worldwide Development at Pfizer. "Early diagnosis and effective treatment is critical since prolonged anxiety increases impairment and worsens the outcome of co-existing illnesses."
The most common adverse events reported by patients were dizziness and drowsiness. Most adverse events were mild to moderate in intensity and generally dose related.
In the United States, Lyrica(R) (pregabalin) C-V capsules are approved for the management of diabetic peripheral neuropathy, post herpetic neuralgia and adjunctive treatment of partial onset seizures. Lyrica is an alpha-2-delta ligand that is believed to work by calming hyper-excited neurons.
Developed by Pfizer, Lyrica has been approved for various neuropathic pain indications including peripheral neuropathic pain, diabetic and post herpetic neuropathic pain and adjunctive therapy for epilepsy in more than 60 countries outside of the United States.
Pfizer Inc
http://www.pfizer.com |
| posted by Jennie Tate @ 6:09 AM |
|
|
|
| Thursday, April 27, 2006 |
| Testes To Incubate Stem Cells - Could Help Young Cancer Patients Undergoing Chemotherapy |
Men may cringe at the idea, but sperm-producing stem cells found in testicles could be extracted, grown in the lab, and frozen for future use. A team in the Netherlands has successfully harvested spermatogonial stem cells from cows and cultured them inside mouse testes. The hope is that the same thing could be done for men. "This is a very promising route to help young cancer patients undergoing chemotherapy," Dirk de Rooij of Utrecht University, Netherlands, told participants gathered at the first EuroSTELLS conference in Venice last month.
The research team were delighted to find abundant bovine spermatogonial stem cells thriving in the mouse testes, since they are hard to spot in tissue sections. Once the researchers learned to isolate these elusive sperm-producing cells from bull calfs, they transplanted them into mouse testes. Despite the foreign surroundings, the bovine cells survived for long periods, up to three months, although they failed to fully develop into sperm, said de Rooij.
"Our plan is to develop a culture system for spermatogonial stem cells" de Rooij told conference attendees. Although admitting the leap to humans is considerable, the colonised mouse testes are already providing useful insights.
"We'd like to know how to culture human spermatogenic stem cells to restore male fertility after cancer therapy," says Hannu Sariola, from the University of Helsinki in Finland who is also working towards a similar goal.
Bizarrely, a brain cell growth factor also has a powerful influence on spermatogonial stem cells. Glial cell derived neurotrophic factor (GDNF) is also involved in spermatogenesis: levels are high during the neonatal period and drop in adulthood. Indeed, mice that have been genetically manipulated to express high levels of GDNF in the testes produce huge clusters of spermatogonial stem cells. But the risk of cancer is boosted too, so it is not just about turning on the GDNF tap indiscriminately. It must be tightly regulated, Sariola pointed out.
The Dutch researchers are also hunting for the ideal conditions and nutrients that will coax spermatogonial stem cells into becoming sperm. So far, they have found that growth factors GDNF and fibroblast growth factor (FGF) seem to be necessary to enhance cell growth. The team's next move is to transplant monkey and human cells into the mouse testes system.
"It is truly remarkable that mouse testes can sustain these bovine cells in culture," says Elaine Dzierzak, who coordinates a EuroSTELLS project at Erasmus University Medical Centre in Rotterdam. Testicular cultures could also prove an ideal system to test compounds that might affect sperm-production such as endocrine disruptors or therapeutic drugs.
###
Contact: Jens Persson
European Science Foundation |
| posted by Jennie Tate @ 4:20 AM |
|
|
|
| Sunday, April 23, 2006 |
| Hypnotherapy Helps Relieve Chest Pain |
Hypnotherapy seems to relieve severe chest pain that is not caused by a heart condition, known as non-cardiac chest pain, suggests a small study published ahead of print in Gut.
Around a third of patients investigated for chest pain thought to be caused by coronary artery disease have no identifiable cause for their pain. Nevertheless they often continue to be severely incapacitated by it, despite reassurances that there is nothing to worry about. Young women seem to be particularly prone to the condition.
The cause of non-cardiac chest pain is unknown, although several factors have been implicated, including acid reflux and psychological problems. The condition is notoriously difficult to treat.
Researchers randomly divided 28 patients with the condition into two groups. One group received 12 sessions of hypnotherapy over 17 weeks; the other group were given "supportive therapy" plus dummy medicine (placebo).
Of the 15 people treated with hypnotherapy, 80% reported significant pain relief, although there was no change in frequency of bouts of pain, compared with just three of the 13 people treated with supportive therapy and placebo.
Hypnotherapy also significantly improved the sense of overall wellbeing and reduced the use of painkillers and other drugs prescribed to control the condition. By contrast, the group treated with supportive therapy increased their drug intake.
Hypnotherapy did not affect levels of anxiety or depression, however, which remained the same as before.
Brain scans of patients treated with hypnotherapy for other conditions show that it directly affects a region of the brain which processes the emotional content of a painful stimulus. And hypnotherapy can also cut levels of gastric acid produced by the stomach.
The authors acknowledge that hypnotherapy is labour intensive and therefore expensive, but so too are the many investigations and drugs given to patients with non-cardiac chest pain, they say.
And previous research carried out by the same authors on patients with irritable bowel syndrome shows that most of them remain well in the long term, requiring far less medication and far fewer visits to their doctors.
###
Emma Dickinson
edickinson@bmj.com
BMJ-British Medical Journal |
| posted by Jennie Tate @ 11:20 AM |
|
|
|
| Saturday, April 22, 2006 |
| FDA Fast Track Designation For Tramadol ER In Painful HIV-associated Neuropathy |
TheraQuest Biosciences, a development stage pain management company today announced that the U.S. Food and Drug Administration (FDA) has designated as a Fast Track product the Company's proprietary, abuse deterrent Tramadol Extended Release (ER) for the treatment of painful HIV-associated neuropathy.
Fast Track designation provides expedited regulatory review for new drugs demonstrating potential to address unmet medical needs for the treatment of serious or life-threatening conditions. Under Fast Track, TheraQuest is now eligible to submit a new drug application (NDA) for Tramadol ER on a rolling basis, allowing the FDA to review sections of the NDA in advance of receiving TheraQuest's full submission.
According to the FDA, Tramadol ER was designated a Fast Track product both because of the seriousness of painful HIV-associated neuropathy and because Tramadol ER demonstrates the potential to provide a therapeutic benefit. There are currently no approved therapies for patients with painful HIV- associated neuropathy.
"Tramadol ER's fast track status underscores the urgency of developing new treatments for patients with painful HIV-associated neuropathy and the potential of Tramadol ER to improve the quality of life of patients with this devastating disease," said Najib Babul, PharmD, President and CEO of TheraQuest. "We look forward to working closely with the Division of Anesthetic, Analgesic and Rheumatology Products at FDA to expedite the development of Tramadol ER for painful HIV-associated neuropathy," added Babul. About Tramadol ER (TQ-1017)
TheraQuest's Tramadol ER (TQ-1017) is a proprietary, extended release once-daily abuse deterrent formulation of tramadol. It demonstrates more robust in vitro abuse deterrent properties than either controlled release oxycodone or marketed Tramadol ER formulations. It is exceedingly difficult to extract the active drug from the formulation using common solvents. It also cannot be crushed for inhalation to obtain rapid euphoria. Without a secure release once-daily tramadol, rapid absorption from intentional or inadvertent crushing has the potential to deliver a massive dose all at once and produce neurological toxicity, including agitation, seizures, coma and respiratory failure.
TheraQuest has been granted 7-years market exclusivity for Tramadol ER by the FDA Office of Orphan Products Development for the "management of post- herpetic neuralgia" and for the "treatment of painful HIV-associated neuropathy." Orphan product designation provides seven years of market exclusivity, 50% R&D Tax Credits, exemption from FDA Prescription Drug User Fee and access to research grants from the Office of Orphan Products Development.
TheraQuest has an open IND in the United States and has recently completed a Phase I study evaluating the pharmacokinetics of once-daily Tramadol ER compared to short-acting Tramadol (Ultram(R)), which is dosed every four to six hours.
TheraQuest Biosciences, LLC |
| posted by Jennie Tate @ 11:06 AM |
|
|
|
| Tuesday, April 18, 2006 |
| Mediterranean Diet Lowers Alzheimer's Risk, Study |
According to a study carried out in New York, those who follow a Mediterranean diet may be protecting themselves from developing Alzheimer's disease.
A Mediterranean diet involves eating more fruit, vegetables, olive oil and cereals and less meat and dairy than the Northern European or North American diet.
The study involved asking 2,258 elderly men to follow a Mediterranean diet for four years. None of them had any form of dementia at the beginning of the study. They were prospectively evaluated every 1.5 years. The main predictors for this group were adjusted for age, sex, ethnicity, education, apolipoprotein E genotype, caloric intake, smoking, medical comorbidity index, and body mass index. During those four years, 262 of them were diagnosed with Alzheimer's disease.
The researchers found that the more people stuck to a Mediterranean diet, the lower were their chances of developing Alzheimer's disease.
The researchers had developed a diet adherence score, from 0 to 9 - nine being the highest. Those with the highest adherence score had a 40% lower risk of Alzheimer's than those at the bottom. Those in the middle had a 15-21% lower risk than those at the bottom.
The researchers said you cannot pinpoint one particular food or ingredient and just use that for protection. The Mediterranean diet, overall, seems to offer the protection.
This is the first large study that looked at a diet in general, rather than particular ingredients in isolation.
Previous research on the Meditteranean diet have revealed many benefits - cardiovascular, longevity, lower incidences of cancer, maintaining good weight - and now, Alzheimer's disease protection.
You can read about this study in Annals of Neurology (April Issue).
The study was funded by:
-- NIH (National Institute on Aging, Columbia University General Clinical Research Center); Grant Number: AG07232, AG07702, AG15294-06, 1K08AG20856-01, RR00645
-- Charles S. Robertson Memorial Gift for Research in Alzheimer's disease
-- Blanchette Hooker Rockefeller Foundation
-- New York City Council Speaker's Fund for Public Health Research
-- Taub Institute for Research on Alzheimer's Disease and the Aging Brain
Written by: Christian Nordqvist
Editor: Medical News Today |
| posted by Jennie Tate @ 10:25 AM |
|
|
|
| Thursday, April 13, 2006 |
| Antioxidants Might Not Protect Against Heart Disease |
Antioxidants, such as beta-carotene and Vitamin E, have been touted for their ability to protect against heart disease. This protective effect is attributed to their ability to prevent the oxidation of bad cholesterol by free radicals - a process thought to contribute to the build-up of disease-causing fatty deposits on artery walls. But a new study, published online on April 10 in The Journal of Experimental Medicine, suggests that the heart-healthy effect of one antioxidant has little to do with cholesterol oxidation.
A group of researchers at the University of New South Wales in Australia, led by Roland Stocker, studied a cholesterol-lowering drug called Probucol (Lorelco) in laboratory rodents with vascular disease. Probucol reduces the risk of heart disease in humans, but is no longer prescribed in the US and Australia because of adverse side effects: a tendency to lower good cholesterol along with the bad and the potential to induce an irregular heartbeat. Probucol is still available in Canada and Europe.
In their new study, Stocker and his colleagues show that the protective effect of probucol has nothing to do with its ability to scavenge oxygen free radicals, as the free radical-busting part of the drug alone was ineffective in protecting animals against heart disease. Instead, a different part of the probucol molecule was doing the beneficial work.
In fact, contrary to widely accepted opinion, the group found no relationship between the levels of oxidized cholesterol in blood vessels and the severity of heart disease. This might help explain the disappointing results of clinical trials with other free radical-scavenging antioxidants, such as Vitamin E, which have shown no protective effect against heart disease in humans.
The protective effect of these compounds depended on the induction of a cellular enzyme called heme oxygenase-1 (HO-1). HO-1 is known to protect against atherosclerosis in animal models, although the mechanism is not completely clear. Not surprisingly, HO-1 was not induced by Vitamin E.
Drugs closely related to probucol that contain the protective part of the drug were just as protective as the original drug. If these probucol relatives - one of which is now being tested in humans - are free of side effects, they may provide a more effective alternative to current therapies.
###
Contact: Nickey Henry
henryn@rockefeller.edu
Journal of Experimental Medicine |
| posted by Jennie Tate @ 11:36 AM |
|
|
|
| Tuesday, April 11, 2006 |
| Fish Oil May Help Protect Against Retinal Degenerative Diseases |
An invited paper published in Trends in Neuroscience this week by Nicolas G. Bazan, MD, PhD, Boyd Professor and Director of the Neuroscience Center of Excellence at LSU Health Sciences Center in New Orleans, reports on the role that the omega-3 fatty acids in fish oil play in protecting cells in the retina from degenerative diseases like retinitis pigmentosa and age-related macular degeneration, the leading cause of loss of vision in those older than 65. The paper is titled, Cell survival matters: docosahexaenoic acid signaling, neuroprotection and photoreceptors.
In these blinding eye diseases, photoreceptor cells (rods and cones) degenerate and die. Although this process can be triggered by many different things, one of the most significant protective factors may be the close association of retinal pigment epithelial (RPE) cells and the amount of docosahexaenoic acid (DHA) in them. The main role of RPE cells is photoreceptor maintenance–they conduct the daily shedding, internalization, and degradation of the tips of the photoreceptor outer segments. It now appears that RPE cells are also key to the survival of photoreceptor cells.
Both photoreceptor and RPE cell types are normally exposed to potentially damaging factors such as sunlight and high oxygen tension.
How the cells avoid damage from these factors and others has been a mystery, up to now. Dr. Bazan's LSUHSC group, in close collaboration with colleagues at Harvard, has made several key discoveries that are beginning to provide answers to this complex riddle. One of them is the importance of DHA. RPE cells cope with sunlight and oxidative stress, as well as trauma, by using antioxidants like Vitamin E, present in the cells. Part of the RPE cells' response is to activate the synthesis of a major neuroprotective compound, which Dr. Bazan and colleagues discovered, called neuroprotectin D1 (NPD1). NPD1 inhibits genes causing inflammation and cell death that oxidative stress and other triggers turn on. RPE cells contain the omega-3 fatty acid family member, DHA, which Dr. Bazan and colleagues found is a precursor to NPD1. RPE cells regulate the uptake, conservation, and delivery of DHA to the photoreceptor cells. DHA, known to be in short supply in patients with retinitis pigmentosa and Usher's syndrome, promotes protective cell signaling by facilitating the expression of helpful rather than destructive proteins as well as stimulating the production of NPD1. DHA and NPD1 also decrease the production of damaging free radicals. DHA has been shown by Dr. Bazan to promote survival and inhibit cell death not only of photoreceptor cells, but also of neurons in an experimental model of Alzheimer's disease.
Questions remain, including the identification of another receptor believed to be an important pathway for NPD1, more information about the signals that control the formation of NPD1, and if NPD1 or a synthetic counterpart might be effective when administered therapeutically.
"Because the early clinical manifestations of most retinal degeneration precedes massive photoreceptor cell death, it is important to define the initial crucial events," notes Dr. Bazan. "This knowledge might be applicable to the design of novel therapeutic interventions to halt or slow disease progression."
###
Contact: Leslie Capo
lcapo@lsuhsc.edu
Louisiana State University Health Science Center |
| posted by Jennie Tate @ 2:38 AM |
|
|
|
| Sunday, April 09, 2006 |
| Weight Loss Drug, Xenical, Moves Closer To OTC Status |
An FDA spokesperson said GSK's weight loss drug, Xenical (orlistat), has received conditional approval for OTC (Over-the-Counter) status. OTC means a drug can be bought without a doctor's prescription.
In order to gain OTC status, GSK (GlaxoSmithKline) will have to take some steps. The spokesperson did not explain what these steps were.
If finally approved, Xenical will be sold as an OTC drug in the USA under the brand name Alli.
Xenical belongs to the Swiss pharmaceutical company, Roche Holding AG. GlaxoSmithKline, a British pharmaceutical company, bought the rights to sell the drug in the USA as a non-prescription drug.
The drug works by preventing fat from being absorbed by the body. The patient has to be careful with what he/she eats. If too much fat is consumed he/she will experience an embarrassing oily discharge (via the anus). Many have written to Medical News Today saying they used Xenical and lost weight (in their opinions) for two reasons: 1. Less fat was absorbed. 2. Because of the nature of the drug, they had to drastically cut down on their fat intake - otherwise their underwear would be stained.
To date, there are not any OTC weight loss drugs that have been endorsed by the FDA.
GSK argues that having the drug available over-the-counter would help fight the ‘obesity epidemic' currently spreading fast in the USA.
The USA has the highest percentage of people experiencing obesity or overweight in the world. However, other countries are catching up fast.
Written by: Christian Nordqvist
Editor: Medical News Today |
| posted by Jennie Tate @ 5:29 AM |
|
|
|
| Friday, April 07, 2006 |
| What Is Pharmacology's Place In Finding Alternatives To Alcohol? |
Journal of Psychopharmacology is proud to be publishing this leading research on the place of pharmacology in finding alternatives for alcohol. The following papers appear in the May 2006 issue:
Critique:
* Alcohol alternatives - a goal for psychopharmacology, by David J Nutt, University of Bristol, UK Commentaries:
* Alcohol alternatives - a goal for psychopharmacology, by Ian Ragan, CIR Consulting UK
* Harm reduction - lessons learned from tobacco control, by Marcus R MunafÃ2, University of Bristol, UK
* For alcohol alternatives, the science is not the hardest part, by Robin Room, Stockholm University, Sweden
* The regulatory challenges in engineering a safer tipple, by Wayne Hall, University of Queensland, Australia
As Prof Nutt, Editor-in-Chief of Journal of Psychopharmacology, outlines in his piece, "Alcohol is a growing problem worldwide that some believe may have already overtaken tobacco in terms of overall health and social care costs because of the consequences of intoxication, such as accidents, with subsequent medical complications."
These papers discuss alternative models to the current approach to the sale and consumption of alcohol, such as removing or reducing alcohol content in drinks sold, especially beers and lager, and offering tax incentives for low alcohol or alcohol-free drinks.
These papers also discuss the scope for further pharmacological investigation into a chemical that can be substituted for alcohol without leading to the same level of misuse and dependence. New partial agonists (PA) could be used that would allow the user to enjoy the pleasurable effects of alcohol consumption but without the associated ill effects, such as memory loss and impaired motor skills.
There would need to be legislative reform governing outlets offering these PAs, but as this could potentially hold the key to eradicating the problems currently associated with alcohol misuse, such legislative reform may well be well placed.
###
About The British Association of Psychopharmacology:
The British Association of Psychopharmacology was founded in 1974, with the general intention of bringing together those from clinical and experimental disciplines as well as members of the pharmaceutical industry involved in the study of psychopharmacology. To this end the Association arranges scientific meetings, fosters research and teaching, encourages publication of results of research and provides guidance and information to the public on matters relevant to psychopharmacology.
About SAGE Publications:
SAGE Publications is a leading international publisher of journals, books, and electronic media for scholarly, educational, and professional markets. Since 1965, SAGE has helped inform and educate a global community of scholars, practitioners, researchers, and students.
Contact: Fiona Barratt
fiona.barratt@sagepub.co.uk
SAGE Publications |
| posted by Jennie Tate @ 6:13 AM |
|
|
|
| Thursday, April 06, 2006 |
| Regular Use Of Popular Prescription Pain Relievers Significantly Reduces The Risk Of Some Cancers |
Results from a new, five-year study show that regular use of popular prescription pain relievers may reduce the risk of breast cancer by up to 71 percent and may offer similar benefit in the prevention of prostate, colon and lung cancers.
The study findings were released today at the annual meeting of the American Association for Cancer Research in Washington, D.C.
"We believe this is the first study to show that selective COX-2 inhibitors have significant chemopreventive effects against breast cancer," says Dr. Randall Harris, professor and director of the Center for Molecular Epidemiology and Environmental Health in The Ohio State University College of Medicine and lead author of the study.
The results come from a larger, case-control study of NSAID use and its impact upon the four leading types of cancer in the United States: breast, lung, prostate and colon cancer. NSAIDs are non-steroidal, anti-inflammatory drugs that block the COX-2 enzyme pathway that is often activated in inflammation, cancer, heart disease and other disorders.
Harris and his colleagues studied the use of celecoxib (Celebrex), rofecoxib (Vioxx), regular aspirin, low-dose aspirin, ibuprofen and acetaminophen among 323 women with breast cancer from 1999-2004.
They compared the results with those from a control group of 649 cancer-free women matched for age, race and county of residence.
They discovered that women who used NSAIDs on a regular basis had less breast cancer. Specifically, they found that those who used celecoxib or rofecoxib for at least two years appeared to benefit the most, experiencing a 71 percent reduction in risk of breast cancer. Ibuprofen use over the same period was associated with a 64 percent reduction, while regular aspirin offered a 51 percent reduction in risk of the disease.
On the other hand, acetaminophen, which has a negligible effect upon COX-2 activity, and low-dose aspirin provided no significant change in the risk of breast cancer.
"The COX-2 signaling pathway is important in cancer because when it's activated, it can stimulate many key steps in cancer development, including cell division, inhibition of cell death, angiogenesis (the creation of new blood vessels to nourish growing tumors) and metastasis," says Harris, who is also a member of the OSU Comprehensive Cancer Center.
Harris says his research group is only midway through analyzing data from the other parts of the study, but adds that early results suggest that regular use of selective COX-2 inhibitors appears to provide about the same magnitude of protection from prostate, lung and colon cancer.
"These results suggest strong potential for regular use of these drugs in cancer prevention. Still, we know these drugs may have side effects, so we are not advising people to go out and start taking them until more studies confirm that they are safe and effective," says Harris.
Celebrex is still widely used for pain relief, but Vioxx was pulled off the market in 2004 following reports of heightened risk of heart attacks.
"It's clear that we need to have multiple retrospective and prospective studies to validate these findings," says Harris, who has been studying the impact of COX-2 inhibitors for many years. "Eventually, we may find that regular intake of a low dose of a COX-2 inhibitor may be enough to reset the COX-2 cascade and safely protect people against cancer."
###
Grants from Pfizer and the National Cancer Institute supported the study.
Study co-authors include Joanne Beebe-Donk and Galal Alshafie, both colleagues in the Center for Molecular Epidemiology and Environmental Health in the OSU College of Medicine.
Contact: Michelle Gailiun
michelle.gailiun@osumc.edu
Ohio State University Medical Center |
| posted by Jennie Tate @ 12:22 AM |
|
|
|
| Wednesday, April 05, 2006 |
| Obesity Rates Among American Women Falling |
While more and more children and adult males are becoming obese in the USA, rates for women seem to be falling. 33.2% of American women were obese in 2004, a slight drop from 33.4% in 2000. This is the first bit of encouraging news regarding the ever-increasing weight of Americans in general over the last twenty years.
Healthcare professionals in the USA say this offers a glimmer of hope. If women adopt healthier lifestyles, this could eventually be passed on to other members of the family.
Unfortunately, men and children are putting on the weight faster than women are losing it.
Why are women bucking the trend?
There could be many reasons. Here are some opinions we received from health care professionals and members of the public:
-- Women tend to seek professional help more than men do (for health).
-- Compliance is better among women (women are better at following instructions, either on a label, or from the people they went to see about a health problem).
-- More literature aimed at women (women's magazines) offer useful advice on weight management and general health, in comparison to literature aimed at men.
-- Women have become better informed about health and nutrition than men (related to the previous point).
-- This sudden slight drop in obesity levels among women could just be a blip.
-- Women are more concerned about how they look than men are.
Written by: Christian Nordqvist
Editor: Medical News Today |
| posted by Jennie Tate @ 8:27 AM |
|
|
|
|
|
